Vanda Pharmaceuticals Inc. (VNDA) SVP Sells $130,747.68 in Stock
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) SVP Gunther Birznieks sold 8,568 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $15.26, for a total transaction of $130,747.68. Following the completion of the transaction, the senior vice president now owns 118,366 shares of the company’s stock, valued at approximately $1,806,265.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Vanda Pharmaceuticals Inc. (VNDA) traded down $0.05 on Thursday, hitting $15.55. 385,547 shares of the company traded hands, compared to its average volume of 468,449. Vanda Pharmaceuticals Inc. has a 52-week low of $11.90 and a 52-week high of $18.99. The firm has a market cap of $698.62, a P/E ratio of -48.59 and a beta of 1.29.
Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, hitting the consensus estimate of ($0.10). Vanda Pharmaceuticals had a negative net margin of 9.01% and a negative return on equity of 10.99%. The firm had revenue of $41.30 million during the quarter, compared to the consensus estimate of $43.90 million. During the same quarter in the prior year, the firm earned ($0.01) EPS. The company’s revenue for the quarter was up 7.3% on a year-over-year basis. analysts predict that Vanda Pharmaceuticals Inc. will post -0.44 earnings per share for the current year.
A number of brokerages have weighed in on VNDA. BidaskClub upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, December 22nd. ValuEngine upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, December 20th. Oppenheimer reiterated a “buy” rating and issued a $25.00 price objective on shares of Vanda Pharmaceuticals in a research report on Sunday, November 12th. Zacks Investment Research downgraded shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, October 26th. Finally, Piper Jaffray Companies set a $26.00 price objective on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, October 19th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Vanda Pharmaceuticals has a consensus rating of “Buy” and an average price target of $21.50.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.